ARL4C and renal cell carcinoma: For patients with RCC, FN1 expression will be useful in combination with a predictive biomarker of poor prognosis such as ARL4C, which predicts patient mortality caused by RCC within 2 years after the initial diagnosis of metastasis with a high accuracy of 97.7% [14].